Fannin Goldenrod Holdings — Full Portfolio
3 tracked investments · listed companies and verified rows first
BiotechHouston, US
Dev Chatterjee(Executive Officer)Leo Linbeck IV(Executive Officer)Mark Worscheh(Executive Officer, Director)Atul Varadhachary(Executive Officer, Director)Leo Linbeck III(Director)Thomas Brenninkmeijer(Director)
Board seatLeo Linbeck III· per SEC Form D · $6.5M raise · filed Jun 2026
HealthtechHouston, US
Reynolds, III M. Delagado(Director)Steve Oldham(Director)Leo III E Linbeck(Director)Benjamin A Hertzog(Executive Officer, Director)Jason J Heuring(Executive Officer)
Board seatLeo E Linbeck, III· per SEC Form D · $64M raise · filed Feb 2024
Pulmotect develops PUL-042, a clinical-stage inhaled therapeutic that stimulates the innate immune system in the lungs to protect against viral, bacterial, and fungal pathogens.
BiotechHealthtechHouston, US
Colin Broom(Executive Officer, Director)Mark Worscheh(Director)Leo Linbeck III(Director)
BoardKumar Srinivasan(Director)Atul Varadhachary(Director)
Board seatLeo E. LinbeckLeo E. Linbeck IIILeo Linbeck III· per SEC Form D · filed Sep 2024
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.